FitEx for Endometrial Cancer Survivors: Initial Efficacy
NCT05737745
Behavior, Body Weight
Roanoke, Virginia, United States
View Trial DetailsNCT Number: NCT02226302
The objective is to develop an organotypic model to assess the effects of obesity on the expression and methylation status of estrogen-responsive genes in endometrial cancer. Omental fat samples will be removed from participants during surgery and these fat samples will be used in laboratory analyses.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Observational
Queen Elizabeth II Jubilee Hospital, Coopers Plains, Queensland, Australia
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Baseline
Omental fat will be collected from 6 lean patients, 6 obese patients and 4 controls (male patients) and co-cultured with endometrial cancer cell lines
Time frame: Baseline
Compare gene response in tissue from lean and obese individuals
Queensland Centre for Gynaecological Cancer
Other Gov
Acronym: FETCH
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05737745
Behavior, Body Weight
Roanoke, Virginia, United States
View Trial DetailsNCT04697264
Body Weight, Endometrial Cancer
Guildford, Surrey, United Kingdom
View Trial DetailsNCT03962140
Atrophy, Body Weight
Truro, Cornwall, United Kingdom
View Trial DetailsNCT03722030
Behavior, Body Weight
Madison, Wisconsin, United States
View Trial Details